Zellzyklus und Apoptose

  • Peter Daniel
Part of the Molekulare Medizin book series (MOLMED)


Die Regulation von Zeilproliferation und Zelltod erfolgt durch eng miteinander verknüpfte Signalwege. Im normalen und ausgereiften, adulten, sich aber dennoch ständig selbst erneuernden Gewebe besteht ein dynamisches Gleichgewicht zwischen Zellproliferation durch mitotische Teilung und Zelluntergang durch programmierten Zelltod (Apoptose) (Kerr et al. 1972; Meier et al. 2000; Evan u. Vousden 2001). Beide Phänomene werden durch komplizierte Regulationssysteme engmaschig kontrolliert (Krammer et al. 1994; Daniel 2000). Dies spiegelt sich auch in der Bedeutung dieser beiden zellbiologischen Phänomene bei der Entstehung von benignen (McDonnell et al. 1989) und malignen Tumoren wieder (Tsujimoto et al. 1984; Vaux et al. 1988; Burns et al. 1991; Yonish-Rouach et al. 1991; Soengas et al. 1999).


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abraham RT (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15:2177–2196PubMedGoogle Scholar
  2. Adams JM, Cory S (1998) The Bcl-2 protein family: arbiters of cell survival. Science 281:1322–1326PubMedGoogle Scholar
  3. Adams PD, Kaelin WG Jr (1996) The cellular effects of E2F overexpression. Curr Top Microbiol Immunol 208:79–93PubMedGoogle Scholar
  4. Adams JM, Huang DC, Puthalakath H et al. (1999) Control of apoptosis in hematopoietic cells by the Bcl-2 family of proteins. Cold Spring Harb Symp Quant Biol 64:351–358PubMedGoogle Scholar
  5. Adjei AA (2001) Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93:1062–1074PubMedGoogle Scholar
  6. Alessi DR, Cohen P (1998) Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 8:55–62PubMedGoogle Scholar
  7. Alessi DR, James SR, Downes CP et al. (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Curr Biol 7:261–269PubMedGoogle Scholar
  8. Almasan A, Linke SP, Paulson TG, Huang LC, Wahl GM (1995) Genetic instability as a consequence of inappropriate entry into and progression through S-phase. Cancer Metastasis Rev 14:59–73PubMedGoogle Scholar
  9. Altieri DC, Marchisio PC, Marchisio C (1999) Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 79:1327–1333PubMedGoogle Scholar
  10. Altura RA, Inukai T, Ashmun RA, Zambetti GP, Roussel MF, Look AT (1998) The chimeric E2A-HLF transcription factor abrogates p53-induced apoptosis in myeloid leukemia cells. Blood 92:1397–13405PubMedGoogle Scholar
  11. Amati B, Dalton S, Brooks MW, Littlewood TD, Evan GI, Land H (1992) Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature 359:423–426PubMedGoogle Scholar
  12. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H (1993a) Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 72:233–245PubMedGoogle Scholar
  13. Amati B, Littlewood TD, Evan GI, Land H (1993b) The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J 12:5083–5087PubMedGoogle Scholar
  14. Bai C, Richman R, Elledge S J (1994) Human cyclin F. EMBO J 13:6087–6098PubMedGoogle Scholar
  15. Banner DW, D’Arcy A, Janes W et al. (1993) Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 73:431–445PubMedGoogle Scholar
  16. Beaupre DM, Kurzrock R (1999) RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol 17:1071–1079PubMedGoogle Scholar
  17. Benedict MA, Hu Y, Inohara N, Nunez G (2000) Expression and functional analysis of Apaf-1 isoforms. Extra Wd-40 repeat is required for cytochrome c binding and regulated activation of procaspase-9. J Biol Chem 275:8461–8468PubMedGoogle Scholar
  18. Bergeron L, Yuan J (1998) Sealing one’s fate: control of cell death in neurons. Curr Opin Neurobiol 8:55–63PubMedGoogle Scholar
  19. Boddy MN, Furnari B, Mondesert O, Russell P (1998) Replication checkpoint enforced by kinases Cds1 and Chk1. Science 280:909–912PubMedGoogle Scholar
  20. Bordeleau LN, Berinstein L (2000) Molecular diagnostics in follicular non-Hodgkin’s lymphoma: a review. Semin Oncol 27:42–52PubMedGoogle Scholar
  21. Bosanquet AG, Sturm I, Wieder T et al. (2002) Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia. Leukemia 16:1035–1044PubMedGoogle Scholar
  22. Bouillet P, Metcalf D, Huang DC et al. (1999) Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286:1735–1738PubMedGoogle Scholar
  23. Britos-Bray M, Ramirez M, Cao W et al. (1998) CBFβeta-SMMHC, expressed in M4eo acute myeloid leukemia, reduces p53 induction and slows apoptosis in hematopoietic cells exposed to DNA-damaging agents. Blood 92:4344–4352PubMedGoogle Scholar
  24. Brondello JM, Boddy MN, Furnari B, Russell P (1999) Basis for the checkpoint signal specificity that regulates Chk1 and Cds1 protein kinases. Mol Cell Biol 19:4262–4269PubMedGoogle Scholar
  25. Bunz F, Dutriaux A, Lengauer C et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497–1501PubMedGoogle Scholar
  26. Burns PA, Kemp CJ, Gannon JV, Lane DP, Bremner R, Balmain A (1991) Loss of heterozygosity and mutational alterations of the p53 gene in skin tumours of interspecific hybrid mice. Oncogene 6:2363–2369PubMedGoogle Scholar
  27. Burtelow MA, Roos-Mattjus PM, Rauen M, Babendure JR, Karnitz LM (2001) Reconstitution and molecular analysis of the hRad9-hHus1-hRad1 (9–1–1) DNA damage responsive checkpoint complex. J Biol Chem 276:25903–25909PubMedGoogle Scholar
  28. Cartwright P, Muller H, Wagener C, Holm K, Heiin K (1998) E2F-6: a novel member of the E2F family is an inhibitor of E2F-dependent transcription. Oncogene 17:611–623PubMedGoogle Scholar
  29. Caspari T, Carr AM (1999) DNA structure checkpoint pathways in Schizosaccharomyces pombe. Biochimie 81:173–181PubMedGoogle Scholar
  30. Catovsky D (1997) The search for genetic clues in chronic lymphocytic leukemia. Hematol Cell Ther [Suppl 1] 39:S5–11Google Scholar
  31. Cerutti L, Simanis V (2000) Controlling the end of the cell cycle. Curr Opin Genet Dev 10:65–69PubMedGoogle Scholar
  32. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B (1999) 14–3–3 Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401:616–620PubMedGoogle Scholar
  33. Chan TA, Hwang PM, Hermeking H, Kinzler KW, Vogelstein B (2000) Cooperative effects of genes controlling the G(2)/M checkpoint. Genes Dev 14:1584–1588PubMedGoogle Scholar
  34. Chen L, Trujillo K, Ramos W, Sung P, Tomkinson AE (2001) Promotion of Dnl4-catalyzed DNA end-joining by the Rad50/Mre11/Xrs2 and Hdf1/Hdf2 complexes. Mol Cell 8:1105–1115PubMedGoogle Scholar
  35. Cheng EH, Kirsch DG, Clem RJ et al. (1997) Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 278:1966–1968PubMedGoogle Scholar
  36. Child ES, Mann DJ (2001) Novel properties of the cyclin encoded by human herpesvirus 8 that facilitate exit from quiescence. Oncogene 20:3311–3322PubMedGoogle Scholar
  37. Chlichlia K, Moldenhauer G, Daniel PT et al. (1995) Immediate effects of reversible HTLV-1 tax function: T-cell activation and apoptosis. Oncogene 10:269–277PubMedGoogle Scholar
  38. Classon M, Dyson N (2001) p107 and p130: versatile proteins with interesting pockets. Exp Cell Res 264:135–147PubMedGoogle Scholar
  39. Clem RJ (2001) Baculoviruses and apoptosis: the good, the bad, and the ugly. Cell Death Differ 8:137–143PubMedGoogle Scholar
  40. Coleman TR, Dunphy WG (1994) Cdc2 regulatory factors. Curr Opin Cell Biol 6:877–882PubMedGoogle Scholar
  41. Coller HA, Grandori C, Tamayo P et al. (2000) Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA 97:3260–3265PubMedGoogle Scholar
  42. Colussi C, Fiumicino S, Giuliani A et al. (2001) 1,2-dimethyl-hydrazine-induced colon carcinoma and lymphoma in msh2(-/-) mice. J Natl Cancer Inst 93:1534–1540PubMedGoogle Scholar
  43. Corradini P, Ladetto M, Inghirami G, Boccadoro M, Pileri A (1994) N- and K-ras oncogenes in plasma cell dyscrasias. Leuk Lymphoma 15:17–20PubMedGoogle Scholar
  44. Cory S, Vaux DL, Strasser A, Harris AW, Adams JM (1999) Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res 59:1685s–1692sPubMedGoogle Scholar
  45. Coutre P le, Tassi E, Varella-Garcia M et al. (2000) Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95:1758–1766PubMedGoogle Scholar
  46. Crompton M (2000) Bax, Bid and the permeabilization of the mitochondrial outer membrane in apoptosis. Curr Opin Cell Biol 12:414–419PubMedGoogle Scholar
  47. Crul M, Klerk GJ de, Beijnen JH, Schellens JH (2001) Ras biochemistry and farnesyl transferase inhibitors: a literature survey. Anticancer Drugs 12:163–184PubMedGoogle Scholar
  48. Daniel PT (2000) Dissecting the pathways to death. Leukemia 14:2035–2044PubMedGoogle Scholar
  49. Daniel PT, Sturm I, Ritschel S et al. (1999) Detection of genomic DNA fragmentation during apoptosis (DNA ladder) and the simultaneous isolation of RNA from low cell numbers. Anal Biochem 266:110–115PubMedGoogle Scholar
  50. Daniel PT, Sturm I, Wieder T, Schulze-Osthoff K (2001) The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 15:1022–1032PubMedGoogle Scholar
  51. Daniel PT, Sturm I, Gillissen B (2002) Tumour genotype and response to cytotoxic gene therapy. In: Subramanian G (ed) Manufacturing of gene therapeutics. Kluwer Academic Publisher, Dordrecht, 1:59–98Google Scholar
  52. Dbaibo GS, Hannun YA (1998) Cytokine response modifier A (CrmA): a strategically deployed viral weapon. Clin Immunol Immunopathol 86:134–140PubMedGoogle Scholar
  53. Desagher S, Osen-Sand A, Nichols A et al. (1999) Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144:891–901PubMedGoogle Scholar
  54. Deveraux QL, Reed JC (1999) IAP family proteins — suppressors of apoptosis. Genes Dev 13:239–252PubMedGoogle Scholar
  55. Dierlamm J, Baens M, Wlodarska I et al. (1999) The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93:3601–3609PubMedGoogle Scholar
  56. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A (1999) The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 190:1025–1032PubMedGoogle Scholar
  57. Donjerkovic DD, Scott W (2000) Regulation of the G1 phase of the mammalian cell cycle. Cell Res 10:1–16PubMedGoogle Scholar
  58. Donnellan R, Chetty R (1998) Cyclin D1 and human neoplasia. Mol Pathol 51:1–7PubMedGoogle Scholar
  59. Druker BJ, Lydon NB (2000) Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105:3–7PubMedGoogle Scholar
  60. Du C, Fang M, Li Y, Lix Wang L (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102:33–42PubMedGoogle Scholar
  61. Dyer C, Sinclair A (1998) The premature ageing syndromes: insights into the ageing process. Age Ageing 27:73–80PubMedGoogle Scholar
  62. Eiben LJ, Duckett CS (1998) The IAP family of apoptotic regulators. Results Probl Cell Differ 24:91–104PubMedGoogle Scholar
  63. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL (1999) Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13:2658–2669PubMedGoogle Scholar
  64. Eischen CM, Roussel MF, Korsmeyer S J, Cleveland JL (2001) Bax loss impairs myc-induced apoptosis and circumvents the selection of p53 mutations during myc-mediated lymphomagenesis. Mol Cell Biol 21:7653–7662PubMedGoogle Scholar
  65. Eisenman RN (2001) Deconstructing myc. Genes Dev 15:2023–2030PubMedGoogle Scholar
  66. Ekert PG, Silke J, Vaux DL (1999) Caspase inhibitors. Cell Death Differ 6:1081–1086PubMedGoogle Scholar
  67. Ekholm SV, Reed SI (2000) Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 12:676–684PubMedGoogle Scholar
  68. Elledge SJ (1998) Mitotic arrest: Mad2 prevents sleepy from waking up the APC. Science 279:999–1000PubMedGoogle Scholar
  69. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S (1998) A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391:43–50PubMedGoogle Scholar
  70. Epstein CJ, Motulsky AG (1996) Werner syndrome: entering the helicase era. Bioessays 18:1025–1027PubMedGoogle Scholar
  71. Erlanson M, Landberg G (2001) Prognostic implications of p27 and cyclin E protein contents in malignant lymphomas. Leuk Lymphoma 40:461–470PubMedGoogle Scholar
  72. Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411:342–348PubMedGoogle Scholar
  73. Evan GI, Wyllie AH, Gilbert CS et al. (1992) Induction of apoptosis in fibroblasts by c-myc protein. Cell 69:119–128PubMedGoogle Scholar
  74. Fang G, Kim CN, Perkins CL et al. (2000) CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 96:2246–2253PubMedGoogle Scholar
  75. Farrow SN, White JH, Martinou I et al. (1995) Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature 374:731–733PubMedGoogle Scholar
  76. Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286:2507–2510PubMedGoogle Scholar
  77. Frei C, Gasser SM (2000) RecQ-like helicases: the DNA replication checkpoint connection. J Cell Sci 113:2641–2646PubMedGoogle Scholar
  78. Friedrich K, Wieder T, Haefen C von et al. (2001) Overexpression of caspase-3 restores sensitivity for drug-induced apoptosis in breast cancer cell lines with acquired drug resistance. Oncogene 20:2749–2760PubMedGoogle Scholar
  79. Fu H, Subramanian RR, Masters SC (2000) 14–3–3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 40:617–647PubMedGoogle Scholar
  80. Funk JO (1999) Cancer cell cycle control. Anticancer Res 19:4772–4780PubMedGoogle Scholar
  81. Gallimore PH, Turnell AS (2001) Adenovirus E1A: remodelling the host cell, a life or death experience. Oncogene 20:7824–7835PubMedGoogle Scholar
  82. Gascoyne RD, Adomat SA, Krajewski S et al. (1997) Prognostic significance of Bcl-2 protein expression and bcl-2-gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood 90:244–251PubMedGoogle Scholar
  83. Geliert M, Hesse JE, Hiom K et al. (1999) V(D)J recombination: links to transposition and double-strand break repair. Cold Spring Harb Symp Quant Biol 64:161–167Google Scholar
  84. Gillett CE, Barnes DM (1998) Demystified… cell cycle. Mol Pathol 51:310–316PubMedGoogle Scholar
  85. Goedecke W, Eijpe M, Offenberg HH, Aalderen M van, Heyting C (1999) Mre11 and Ku70 interact in somatic cells, but are differentially expressed in early meiosis. Nat Genet 23:194–198PubMedGoogle Scholar
  86. Grana X, Garriga J, Mayol X (1998) Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene 17:3365–3383PubMedGoogle Scholar
  87. Griffiths SD, Clarke AR, Healy LE et al. (1997) Absence of p53 permits propagation of mutant cells following genotoxic damage. Oncogene 14:523–531PubMedGoogle Scholar
  88. Gronbaek K, Nully Brown P de, Moller MB et al. (2000) Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin’s lymphoma. Leukemia 14:1727–1735PubMedGoogle Scholar
  89. Groth A, Weber JD, Willumsen BM, Sherr CJ, Roussel MF (2000) Oncogenic Ras induces p19ARF and growth arrest in mouse embryo fibroblasts lacking p21Cip1 and p27Kip1 without activating cyclin D-dependent kinases. J Biol Chem 275:27.473–27.480Google Scholar
  90. Guidez F, Zelent A (2001) Role of nuclear receptor compressors in leukemogenesis. Curr Top Microbiol Immunol 254:165–185PubMedGoogle Scholar
  91. Guo A, Salomoni P, Luo J et al. (2000) The function of PML in p53-dependent apoptosis. Nat Cell Biol 2:730–736PubMedGoogle Scholar
  92. Gutierrez MI, Cherney B, Hussain A et al. (1999) Bax is frequently compromised in Burkitfs lymphomas with irreversible resistance to Fas-induced apoptosis. Cancer Res 59:696–703PubMedGoogle Scholar
  93. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC (1993) bcl-2-gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 82:1820–1828PubMedGoogle Scholar
  94. Hannun YA, Luberto C (2000) Ceramide in the eukaryotic stress response. Trends Cell Biol 10:73–80PubMedGoogle Scholar
  95. Harris CA, Johnson EM Jr (2001) Bh3-only bcl-2 family members are coordinately regulated by the jnk pathway and require bax to induce apoptosis in neurons. J Biol Chem 276:37754–37760PubMedGoogle Scholar
  96. Harrison CJ (2001) The detection and significance of chromosomal abnormalities in childhood acute lymphoblastic leukaemia. Blood Rev 15:49–59PubMedGoogle Scholar
  97. Hay TJ, Meek DW (2000) Multiple sites of in vivo phosphorylation in the MDM 2 oncoprotein cluster within two important functional domains. FEBS Lett 478:183–186PubMedGoogle Scholar
  98. Hayashi Y (2000) The molecular genetics of recurring chromosome abnormalities in acute myeloid leukemia. Semin Hematol 37:368–380PubMedGoogle Scholar
  99. Hecht JL, Aster JC (2000) Molecular biology of Burkitfs lymphoma. J Clin Oncol 18:3707–3721PubMedGoogle Scholar
  100. Hemmati PG, Guussen B, Haefen C von et al. (2002) Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis. Oncogene 21:3149–3461PubMedGoogle Scholar
  101. Hengstschlager M, Braun K, Soucek T, Miloloza A, Hengstschlager-Ottnad E (1999) Cyclin-dependent kinases at the G1-S transition of the mammalian cell cycle. Mutat Res 436:1–9PubMedGoogle Scholar
  102. Hickson ID, Davies SL, Li JL et al. (2001) Role of the Bloom’s syndrome helicase in maintenance of genome stability. Biochem Soc Trans 29:201–204PubMedGoogle Scholar
  103. Hirano T (2000) Chromosome cohesion, condensation, and separation. Annu Rev Biochem 69:115–144PubMedGoogle Scholar
  104. Hochhaus A, Kreil S, Corbin A et al. (2001) Roots of clinical resistance to STI-571 cancer therapy. Science 293:2163PubMedGoogle Scholar
  105. Hoeijmakers JH (2001) Genome maintenance mechanisms for preventing cancer. Nature 411:366–374PubMedGoogle Scholar
  106. Honda R, Yasuda H (1999) Association of pl9(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18:22–27PubMedGoogle Scholar
  107. Hsu SY, Kaipia A, McGee E, Lomeli M, Hsueh AJ (1997) Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members. Proc Natl Acad Sci USA 94:12401–12406PubMedGoogle Scholar
  108. Hu Y, Ding L, Spencer DM, Nunez G (1998) WD-40 repeat region regulates Apaf-1 self-association and procaspase-9 activation. J Biol Chem 273:33489–33494PubMedGoogle Scholar
  109. Hunt T (1991) Cyclins and their partners: from a simple idea to complicated reality. Semin Cell Biol 2:213–222PubMedGoogle Scholar
  110. Ichikawa A, Hotta T, Saito H (1993) Mutations of the p53 gene in B-cell lymphoma. Leuk Lymphoma 11:21–25PubMedGoogle Scholar
  111. Inaba T, Inukai T, Yoshihara T et al. (1996) Reversal of apoptosis by the leukaemia-associated E2A-HLF chimaeric transcription factor. Nature 382:541–544PubMedGoogle Scholar
  112. Inohara N, Ding L, Chen S, Nunez G (1997) Harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J 16:1686–1894PubMedGoogle Scholar
  113. Inukai T, Inoue A, Kurosawa H et al. (1999) SLUG, a ces-1-related zinc finger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein. Mol Cell 4:343–352PubMedGoogle Scholar
  114. Irwin MS, Kaelin WG (2001) p53 family update: p73 and p63 develop their own identities. Cell Growth Differ 12:337–349PubMedGoogle Scholar
  115. Isaacson PG (1999) Mucosa-associated lymphoid tissue lymphoma. Semin Hematol 36:139–147PubMedGoogle Scholar
  116. Ivanov EL, Haber JE (1997) DNA repair: RAD alert. Curr Biol 7:R492–R495PubMedGoogle Scholar
  117. Jackson SP (1997) DNA-dependent protein kinase. Int J Biochem Cell Biol 29:935–938PubMedGoogle Scholar
  118. Jackson CE, Puck JM (1999) Autoimmune lymphoproliferative syndrome, a disorder of apoptosis. Curr Opin Pediatr 11:521–527PubMedGoogle Scholar
  119. Jeggo PA (1998) DNA breakage and repair. Adv Genet 38:185–218PubMedGoogle Scholar
  120. Jeggo PA, Jackson SP, Taccioli GE (1996) Identification of the catalytic subunit of DNA dependent protein kinase as the product of the mouse Scid gene. Curr Top Microbiol Immunol 217:79–89PubMedGoogle Scholar
  121. Jeggo PA, Carr AM, Lehmann AR (1998) Splitting the ATM: distinct repair and checkpoint defects in ataxia-telangiectasia. Trends Genet 14:312–316PubMedGoogle Scholar
  122. Jiang Y, Woronicz JD, Liu W, Goeddel DV (1999) Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science 283:543–546PubMedGoogle Scholar
  123. Johnson DG, Schneider-Broussard R (1998) Role of E2F in cell cycle control and cancer. Front Biosci 3:d447–448PubMedGoogle Scholar
  124. Johnson DG, Walker CL (1999) Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 39:295–312PubMedGoogle Scholar
  125. Jost CA, Marin MC, Kaelin WG Jr (1997) p73 is a simian p53-related protein that can induce apoptosis. Nature 389:191–194PubMedGoogle Scholar
  126. Jürgensmeier JM, Xie ZH, Deveraux Q, Ellerby L, Bredesen D, Reed JC (1998) Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 95:4997–5002PubMedGoogle Scholar
  127. Kadowaki Y, Fujiwara T, Fukazawa T et al. (1999) Induction of differentiation-dependent apoptosis in human esophageal squamous cell carcinoma by adenovirus-mediated p21sdi1 gene transfer. Clin Cancer Res 5:4233–4241PubMedGoogle Scholar
  128. Kaelin WG Jr (1999) Functions of the retinoblastoma protein. Bioessays 21:950–958PubMedGoogle Scholar
  129. Kaghad M, Bonnet H, Yang A et al. (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809–819PubMedGoogle Scholar
  130. Kannan K, Amariglio N, Rechavi G et al. (2001a) DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 20:2225–2234PubMedGoogle Scholar
  131. Kannan K, Kaminski N, Rechavi G, Jakob-Hirsch J, Amariglio N, Givol D (2001b) DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1. Oncogene 20:3449–3455PubMedGoogle Scholar
  132. Karin M (1999) How NF-κB is activated: the role of the IκB kinase (IKK) complex. Oncogene 18:6867–6874PubMedGoogle Scholar
  133. Karin M, Delhase M (2000) The IκB kinase (IKK) and NFjcB: key elements of proinflammatory signalling. Semin Immunol 12:85–98PubMedGoogle Scholar
  134. Kasof GM, Gomes BC (2001) Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 276:3238–3246PubMedGoogle Scholar
  135. Kasten MM, Giordano A (1998) pRb and the cdks in apoptosis and the cell cycle. Cell Death Differ 5:132–140PubMedGoogle Scholar
  136. Kastan MB, Lim DS (2000) The many substrates and functions of ATM. Nat Rev Mol Cell Biol 1:179–186PubMedGoogle Scholar
  137. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304–6311PubMedGoogle Scholar
  138. Katayose Y, Kim M, Rakkar AN, Li Z, Cowan KH, Seth P (1997) Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 57:5441–5445PubMedGoogle Scholar
  139. Kaufmann WK (1995) Cell cycle checkpoints and DNA repair preserve the stability of the human genome. Cancer Metastasis Rev 14:31–41PubMedGoogle Scholar
  140. Kerr JF, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239–257PubMedGoogle Scholar
  141. Kersey JH, Wang D, Oberto M (1998) Resistance of t(4;11) (MLL-AF4 fusion gene) leukemias to stress-induced cell death: possible mechanism for extensive extramedullary accumulation of cells and poor prognosis. Leukemia 12:1561–1564PubMedGoogle Scholar
  142. Keyomarsi KT, Herliczek W (1997) The role of cyclin E in cell proliferation, development and cancer. Prog Cell Cycle Res 3:171–191PubMedGoogle Scholar
  143. Kim ST, Lim DS, Canman CE, Kastan MB (1999) Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem 274:37.538–37.543Google Scholar
  144. Kim DR, Park SJ, Oettinger MA (2000) V(D)J recombination: site-specific cleavage and repair. Mol Cells 10:367–374PubMedGoogle Scholar
  145. Kischkel FC, Hellbardt S, Behrmann I et al. (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 14:5579–5588PubMedGoogle Scholar
  146. Kischkel FC, Lawrence DA, Tinel A et al. (2001) Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 2:2Google Scholar
  147. Kitada S, Andersen J, Akar S et al. (1998) Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 91:3379–3389PubMedGoogle Scholar
  148. Kitagawa M, Yamaguchi S, Takahashi M, Tanizawa T, Hirokawa K, Kamiyama R (1998) Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia 12:486–492PubMedGoogle Scholar
  149. Klasa RJ, List AF, Cheson BD (2001) Rational approaches to design of therapeutics targeting molecular markers. Hematology (Am Soc Hematol Educ Program):443–462Google Scholar
  150. Kolodner RD, Marsischky GT (1999) Eukaryotic DNA mismatch repair. Curr Opin Genet Dev 9:89–96PubMedGoogle Scholar
  151. Krammer PH (2000) CD95’s deadly mission in the immune system. Nature 407:789–795PubMedGoogle Scholar
  152. Krammer PH, Behrmann I, Daniel P, Dhein J, Debatin KM (1994) Regulation of apoptosis in the immune system. Curr Opin Immunol 6:279–289PubMedGoogle Scholar
  153. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B, Scheidereit C (1999) Molecular mechanisms of constitutive NFκB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 18:943–953PubMedGoogle Scholar
  154. Kroemer GJ, Reed C (2000) Mitochondrial control of cell death. Nat Med 6:513–519PubMedGoogle Scholar
  155. Kuhnel F, Zender L, Paul Y et al. (2000) NFκB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J Biol Chem 275:6421–6427PubMedGoogle Scholar
  156. Kuntzel H, Schulz A, Ehbrecht IM (1996) Cell cycle control and initiation of DNA replication in Saccharomyces cerevisiae. Biol Chem 377:481–487PubMedGoogle Scholar
  157. Kurotaki H, Tsushima Y, Nagai K, Yagihashi S (2000) Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Acta Haematol 102:115–123PubMedGoogle Scholar
  158. Larner JM, Lee H, Hamlin JL (1997) S phase damage sensing checkpoints in mammalian cells. Cancer Surv 29:25–45PubMedGoogle Scholar
  159. Lee H, Arsura M, Wu M, Duyao M, Buckler AJ, Sonenshein GE (1995) Role of Rel-related factors in control of c-myc-gene transcription in receptor-mediated apoptosis of the murine B cell WEHI 231 line. J Exp Med 181:1169–1177PubMedGoogle Scholar
  160. Lenny N, Westendorf JJ, Hiebert SW (1997) Transcriptional regulation during myelopoiesis. Mol Biol Rep 24:157–168PubMedGoogle Scholar
  161. Li AJ, Blow J (2001) The origin of CDK regulation. Nat Cell Biol 3:E182–184PubMedGoogle Scholar
  162. Li P, Nijhawan D, Budihardjo I et al. (1997) Cytochrome c and dATP-dependent formation of Apaf-l/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479–489PubMedGoogle Scholar
  163. Li F, Ackermann EJ, Bennett CF et al. (1999) Pleiotropic celldivision defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1:461–466PubMedGoogle Scholar
  164. Lieber MR, Grawunder U, Wu X, Yaneva M (1997) Tying loose ends: roles of Ku and DNA-dependent protein kinase in the repair of double-strand breaks. Curr Opin Genet Dev 7:99–104PubMedGoogle Scholar
  165. Lim DS, Kim ST, Xu B et al. (2000) ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. Nature 404:613–617PubMedGoogle Scholar
  166. Lin AW, Lowe SW (2001) Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc Nati Acad Sci USA 98:5025–5030Google Scholar
  167. Liu Q, Guntuku S, Cui XS et al. (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14:1448–1459PubMedGoogle Scholar
  168. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A et al. (2001) Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 357:39–40PubMedGoogle Scholar
  169. Loeb LA, Kunkel TA (1982) Fidelity of DNA synthesis. Annu Rev Biochem 51:429–457PubMedGoogle Scholar
  170. Lowe SW (1995) Cancer therapy and p53. Curr Opin Oncol 7:547–553PubMedGoogle Scholar
  171. Lucas PC, Yonezumi M, Inohara N et al. (2001) Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NFκB signaling pathway. J Biol Chem 276:19012–19019PubMedGoogle Scholar
  172. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94:481–490PubMedGoogle Scholar
  173. Lydall D, Weinert T (1996) From DNA damage to cell cycle arrest and suicide: a budding yeast perspective. Curr Opin Genet Dev 6:4–11PubMedGoogle Scholar
  174. Maaser K, Hopfner M, Jansen A et al. (2001) Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer 85:1771–1780PubMedGoogle Scholar
  175. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin AS Jr, Mayo MW (2000) Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NFκB. Mol Cell Biol 20:1626–1638PubMedGoogle Scholar
  176. Malumbres M, Pellicer A (1998) RAS pathways to cell cycle control and cell transformation. Front Biosci 3:d887–912PubMedGoogle Scholar
  177. Martinou JC, Green DR (2001) Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2:63–67PubMedGoogle Scholar
  178. Matsuoka S, Huang M, Elledge S J (1998) Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282:1893–1897PubMedGoogle Scholar
  179. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ (2000) Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 97:10389–10394PubMedGoogle Scholar
  180. Mauro MJ, Druker BJ (2001) STI571: a gene product-targeted therapy for leukemia. Curr Oncol Rep 3:223–227PubMedGoogle Scholar
  181. McCormick F (2000) Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015. Semin Cancer Biol 10:453–459PubMedGoogle Scholar
  182. McDonnell TJ, Korsmeyer S J (1991) Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 349:254–256PubMedGoogle Scholar
  183. McDonnell TJ, Deane N, Piatt FM et al. (1989) Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57:79–88PubMedGoogle Scholar
  184. McMurray HR, Nguyen D, Westbrook TF, McAnce DJ (2001) Biology of human papillomaviruses. Int J Exp Pathol 82:15–33PubMedGoogle Scholar
  185. Meier P, Finch A, Evan G (2000) Apoptosis in development. Nature 407:796–801PubMedGoogle Scholar
  186. Millar JB, Russell P (1992) The cdc25 M-phase inducer: an unconventional protein phosphatase. Cell 68:407–410PubMedGoogle Scholar
  187. Moberg KH, Bell DW, Wahrer DC, Haber DA, Hariharan IK (2001) Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 413:311–316PubMedGoogle Scholar
  188. Molinari M (2000) Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif 33:261–274PubMedGoogle Scholar
  189. Morgan SE, Kastan MB (1997) p53 and ATM: cell cycle, cell death, and cancer. Adv Cancer Res 71:1–25PubMedGoogle Scholar
  190. Moser BA, Russell P (2000) Cell cycle regulation in Schizosaccharomyces pombe. Curr Opin Microbiol 3:631–636PubMedGoogle Scholar
  191. Muller H, Heiin K (2000) The E2F transcription factors: key regulators of cell proliferation. Biochim Biophys Acta 1470:M1–12PubMedGoogle Scholar
  192. Müller H, Bracken AP, Vernell R et al. (2001) E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev 15:267–285PubMedGoogle Scholar
  193. Muzio M, Chinnaiyan AM, Kischkel FC et al. (1996) FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85:817–827PubMedGoogle Scholar
  194. Nagamura-Inoue T, Tamura T, Ozato K (2001) Transcription factors that regulate growth and differentiation of myeloid cells. Int Rev Immunol 20:83–105PubMedGoogle Scholar
  195. Nagata S (1998) Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model. J Hum Genet 43:2–8PubMedGoogle Scholar
  196. Nakagawa T, Zhu H, Morishima N et al. (2000) Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403:98–103PubMedGoogle Scholar
  197. Nakano K, Wousden KH (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7:683–694PubMedGoogle Scholar
  198. Nesbit CE, Tersak JM, Prochownik EV (1999) MYC oncogenes and human neoplastic disease. Oncogene 18:3004–3016PubMedGoogle Scholar
  199. Nicholson DW (1999) Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 6:1028–1042PubMedGoogle Scholar
  200. Nigg EA (2001) Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2:21–32PubMedGoogle Scholar
  201. Nilsson I, Hoffmann I (2000) Cell cycle regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res 4:107–114PubMedGoogle Scholar
  202. O’Connor L, Strasser A, O’Reilly LA et al. (1998) Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 17:384–395PubMedGoogle Scholar
  203. Oda E, Ohki R, Murasawa H et al. (2000) Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288:1053–1058PubMedGoogle Scholar
  204. Ohi R, Gould KL (1999) Regulating the onset of mitosis. Curr Opin Cell Biol 11:267–273PubMedGoogle Scholar
  205. Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609–619PubMedGoogle Scholar
  206. Osada M, Ohba M, Kawahara C et al. (1998) Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 4:839–843PubMedGoogle Scholar
  207. Pandolfi PP (2001) Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. Hum Mol Genet 10:769–775PubMedGoogle Scholar
  208. Parker JE, Mufti GJ (2001) The role of apoptosis in the pathogenesis of the myelodysplastic syndromes. Int J Hematol 73:416–428PubMedGoogle Scholar
  209. Peltomaki P (2001) DNA mismatch repair and cancer. Mutat Res 488:77–85PubMedGoogle Scholar
  210. Perez D, White E (1998) E1B 19 K inhibits Fas-mediated apoptosis through FADD-dependent sequestration of FLICE. J Cell Biol 141:1255–1266PubMedGoogle Scholar
  211. Perkins ND (2000) The Rel/NFκB family: friend and foe. Trends Biochem Sci 25:434–440PubMedGoogle Scholar
  212. Peters JM (1999) Subunits and substrates of the anaphase-promoting complex. Exp Cell Res 248:339–349PubMedGoogle Scholar
  213. Petrini JH (2000) The Mre11 complex and ATM: collaborating to navigate S phase. Curr Opin Cell Biol 12:293–296PubMedGoogle Scholar
  214. Pinyol M, Cobo F, Bea S et al. (1998) pl6(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin’s lymphomas. Blood 91:2977–2984PubMedGoogle Scholar
  215. Pipas JM, Levine AJ (2001) Role of T antigen interactions with p53 in tumorigenesis. Semin Cancer Biol 11:23–30PubMedGoogle Scholar
  216. Polster BM, Kinnally KW, Fiskum G (2001) BH3 death domain peptide induces cell type-selective mitochondrial outer membrane permeability. J Biol Chem 276:37887–37894PubMedGoogle Scholar
  217. Prokop A, Wieder T, Sturm I et al. (2000) Relapse in childhood acute lymphoblastic leukemia is associated with decrease of Bax/Bcl-2-ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 14:1606–1613PubMedGoogle Scholar
  218. Putcha GV, Moulder KL, Golden JP et al. (2001) Induction of BIM, a proapoptotic BH3-only Bcl-2 family member, is critical for neuronal apoptosis. Neuron 29:615–628PubMedGoogle Scholar
  219. Puthalakath H, Huang DC, O’Reilly LA, King SM, Strasser A (1999) The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 3:287–296PubMedGoogle Scholar
  220. Puthalakath H, Villunger A, O’Reilly LA et al. (2001) Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 293:1829–1832PubMedGoogle Scholar
  221. Radetzki S, Könne CH, Haefen C von et al. (2002) The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1 overexpressing breast cancer cell lines. Oncogene 21:227–238PubMedGoogle Scholar
  222. Raisova M, Bektas M, Wieder T et al. (2000) Resistance to CD95/Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release. FEBS Lett 473:27–32PubMedGoogle Scholar
  223. Raisova M, Hossini AM, Eberle J et al. (2001) The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol 117:333–340PubMedGoogle Scholar
  224. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL (1996) Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 88:4275–4287PubMedGoogle Scholar
  225. Rampino N, Yamamoto H, Ionov Y et al. (1997) Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275:967–969PubMedGoogle Scholar
  226. Rao RV, Hermel E, Castro-Obregon S et al. (2001) Coupling endoplasmic reticulum stress to the cell death program. Mechanism of caspase activation. J Biol Chem 276: 33869–33874PubMedGoogle Scholar
  227. Rauen M, Burtelow MA, Dufault VM, Karnitz LM (2000) The human checkpoint protein hRad17 interacts with the PCNA-like proteins hRad1, hHus1, and hRad9. J Biol Chem 275:29767–29771PubMedGoogle Scholar
  228. Rayet B, Gelinas C (1999) Aberrant rel/NFκB genes and activity in human cancer. Oncogene 18:6938–6947PubMedGoogle Scholar
  229. Rhind N, Russell P (1998) Mitotic DNA damage and replication checkpoints in yeast. Curr Opin Cell Biol 10:749–758PubMedGoogle Scholar
  230. Rhind N, Russell P (2000) Checkpoints: it takes more than time to heal some wounds. Curr Biol 10:R908–911PubMedGoogle Scholar
  231. Rhind N, Russell P (2001) Roles of the mitotic inhibitors Wee1 and Mik1 in the G(2) DNA damage and replication checkpoints. Mol Cell Biol 21:1499–1508PubMedGoogle Scholar
  232. Richter BW, Mir SS, Eiben LJ et al. (2001) Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol Cell Biol 21:4292–4301PubMedGoogle Scholar
  233. Rodenhuis S (1992) ras and human tumors. Semin Cancer Biol 3:241–247PubMedGoogle Scholar
  234. Roovers KR, Assoian K (2000) Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays 22:818–826PubMedGoogle Scholar
  235. Roussel MF (1999) The INK4 family of cell cycle inhibitors in cancer. Oncogene 18:5311–5317PubMedGoogle Scholar
  236. Rozenfeld-Granot G, Toren A, Amariglio N, Brok-Simoni F, Rechavi G (2001) Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies. Exp Hematol 29:228–233PubMedGoogle Scholar
  237. Rubnitz JE, Pui CH, Downing JR (1999) The role of TEL fusion genes in pediatric leukemias. Leukemia 13:6–13PubMedGoogle Scholar
  238. Russell P (1998) Checkpoints on the road to mitosis. Trends Biochem Sci 23:399–402PubMedGoogle Scholar
  239. Ryan KM, Ernst MK, Rice NR, Vousden KH (2000) Role of NFκB in p53-mediated programmed cell death. Nature 404:892–897PubMedGoogle Scholar
  240. Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeid M (1998) PTEN gene alterations in lymphoid neoplasms. Blood 92:3410–3415PubMedGoogle Scholar
  241. Samali A, Cai J, Zhivotovsky B, Jones DP, Orrenius S (1999) Presence of a pre-apoptotic complex of pro-caspase-3, Hsp60 and Hsp10 in the mitochondrial fraction of jurkat cells. EMBO J 18:2040–2048PubMedGoogle Scholar
  242. Sanchez Y, Wong C, Thoma RS et al. (1997) Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277:1497–1501PubMedGoogle Scholar
  243. Sandig V, Brand K, Herwig S, Lukas J, Bartek J, Strauss M (1997) Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 3:313–319PubMedGoogle Scholar
  244. Savill J, Fadok V (2000) Corpse clearance defines the meaning of cell death. Nature 407:784–788PubMedGoogle Scholar
  245. Sawyers CL (1997) Signal transduction pathways involved in BCR-ABL transformation. Baillieres Clin Haematol 10:223–231PubMedGoogle Scholar
  246. Scheid MP, Duronio V (1998) Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation. Proc Natl Acad Sci USA 95:7439–7444PubMedGoogle Scholar
  247. Schmitt CA, McCurrach ME, Stanchina E de, Wallace-Brodeur RR, Lowe SW (1999) INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev 13:2670–2677PubMedGoogle Scholar
  248. Schwab M, Tyers M (2001) Cell cycle. Archipelago of destruction. Nature 413:268–269PubMedGoogle Scholar
  249. Senderowicz AM (2000) Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 19:6600–6606PubMedGoogle Scholar
  250. Serrano M (2000) The INK4a/ARF locus in murine tumorigenesis. Carcinogenesis 21:865–869PubMedGoogle Scholar
  251. Shaul Y (2000) c-Abl: activation and nuclear targets. Cell Death Differ 7:10–16PubMedGoogle Scholar
  252. Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501–1512PubMedGoogle Scholar
  253. Sherr CJ, Weber JD (2000) The ARF/p53 pathway. Curr Opin Genet Dev 10:94–99PubMedGoogle Scholar
  254. Shimizu S, Ide T, Yanagida T, Tsujimoto Y (2000a) Electrophysiological study of a novel large pore formed by Bax and the voltage-dependent anion channel that is permeable to cytochrome c. J Biol Chem 275:12.321–12.325Google Scholar
  255. Shimizu S, Shinohara Y, Tsujimoto Y (2000b) Bax and Bcl-xL independently regulate apoptotic changes of yeast mitochondria that require VDAC but not adenine nucleotide translocator. Oncogene 19:4309–4318PubMedGoogle Scholar
  256. Siebert R, Willers CP, Opalka B (1996) Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma. Leuk Lymphoma 23:505–520PubMedGoogle Scholar
  257. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J (1996) Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 2:912–917PubMedGoogle Scholar
  258. Skibbens RV, Hieter P (1998) Kinetochores and the checkpoint mechanism that monitors for defects in the chromosome segregation machinery. Annu Rev Genet 32:307–337PubMedGoogle Scholar
  259. Skowyra D, Craig KL, Tyers M, Elledge SJ, Harper JW (1997) F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex. Cell 91:209–219PubMedGoogle Scholar
  260. Smider V, Chu G (1997) The end-joining reaction in V(D)J recombination. Semin Immunol 9:189–197PubMedGoogle Scholar
  261. Smits VA, Medema RH (2001) Checking out the G(2)/M transition. Biochim Biophys Acta 1519:1–12PubMedGoogle Scholar
  262. Soengas MS, Alarcon RM, Yoshida H et al. (1999) Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284:156–159PubMedGoogle Scholar
  263. Soengas MS, Capodieci P, Polsky D et al. (2001) Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409:207–211PubMedGoogle Scholar
  264. Soussi T, Jonveaux P (1991) p53 gene alterations in human hematological malignancies: a review. Nouv Rev Fr Hematol 33:477–480PubMedGoogle Scholar
  265. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES (1998) Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1:949–957PubMedGoogle Scholar
  266. Srinivasula SM, Hegde R, Saleh A et al. (2001) A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410:112–116PubMedGoogle Scholar
  267. Stambolic V, Mak TW, Woodgett JR (1999) Modulation of cellular apoptotic potential: contributions to oncogenesis. Oncogene 18:6094–103PubMedGoogle Scholar
  268. Stern B, Nurse P (1996) A quantitative model for the cdc2 control of S phase and mitosis in fission yeast. Trends Genet 12:345–350PubMedGoogle Scholar
  269. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI (2001) Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413:316–322Google Scholar
  270. Sturm I, Kohne CH, Wolff G et al. (1999) Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 17:1364–1374PubMedGoogle Scholar
  271. Sturm I, Papadopoulos S, Hillebrand T et al. (2000) Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 gene. Int J Cancer 87:517–521PubMedGoogle Scholar
  272. Sturm I, Petrowsky H, Volz R et al. (2001) Analysis of p53/BAX/p16ink4a/CDKN2 in esophageal squamous cell carcinoma: high BAX and p16ink4a/CDKN2 identifies patients with good prognosis. J Clin Oncol 19:2272–2281PubMedGoogle Scholar
  273. Subramanian T, Tarodi B, Chinnadurai G (1995) Functional similarity between adenovirus E1B 19-kDa protein and proteins encoded by Bcl-2 proto-oncogene and Epstein-Barr virus BHRF1 gene. Curr Top Microbiol Immunol 199:153–161PubMedGoogle Scholar
  274. Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169–1178PubMedGoogle Scholar
  275. Susin SA, Lorenzo HK, Zamzami N et al. (1999) Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397:441–446PubMedGoogle Scholar
  276. Suzuki R, Kuroda H, Komatsu H et al. (1999) Selective usage of D-type cyclins in lymphoid malignancies. Leukemia 13:1335–1342PubMedGoogle Scholar
  277. Takizawa CG, Morgan DO (2000) Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr Opin Cell Biol 12:658–665PubMedGoogle Scholar
  278. Tamrakar S, Rubin E, Ludlow JW (2000) Role of pRB dephosphorylation in cell cycle regulation. Front Biosci 5:D121–137PubMedGoogle Scholar
  279. Tan B, Piwnica-Worms D, Ratner L (2000) Multidrug resistance transporters and modulation. Curr Opin Oncol 12:450–458PubMedGoogle Scholar
  280. Taylor SS, McKeon F (1997) Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage. Cell 89:727–735PubMedGoogle Scholar
  281. Taylor WR, Stark GR (2001) Regulation of the G2/M transition by p53. Oncogene 20:1803–1815PubMedGoogle Scholar
  282. Teofili L, Martini M, Di Mario A et al. (2001) Expression of p15(ink4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. Blood 98:495–497PubMedGoogle Scholar
  283. Tibbetts RS, Cortez D, Brumbaugh KM et al. (2000) Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev 14:2989–3002PubMedGoogle Scholar
  284. Tschan MP, Grob TJ, Peters UR et al. (2000) Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia. Biochem Biophys Res Commun 277:62–65PubMedGoogle Scholar
  285. Tschopp J, Martinon F, Hofmann K (1999) Apoptosis: silencing the death receptors. Curr Biol 9:R381–R384PubMedGoogle Scholar
  286. Tsujimoto Y, Shimizu S (2000) VDAC regulation by the Bcl-2 family of proteins. Cell Death Differ 7:1174–1181PubMedGoogle Scholar
  287. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM (1984) Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226:1097–1099PubMedGoogle Scholar
  288. Tsujimoto Y, Cossman J, Jaffe E, Croce CM (1985) Involvement of the bcl-2-gene in human follicular lymphoma. Science 228:1440–1443PubMedGoogle Scholar
  289. Tzivion G, Avruch J (2001) 14–3–3 Proteins: active cofactors in cellular regulation by serine/threonine phosphorylation. J Biol Chem 14:14Google Scholar
  290. Vandenberghe E, De Wolf-Peeters C, van den Oord J et al. (1991) Translocation (11;14): a cytogenetic anomaly associated with B-cell lymphomas of non-follicle centre cell lineage. J Pathol 163:13–18PubMedGoogle Scholar
  291. Vaux DL, Cory S, Adams JM (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440–442PubMedGoogle Scholar
  292. Venkitaraman AR (2001) Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci 114:3591–3598PubMedGoogle Scholar
  293. Vidal A, Koff A (2000) Cell-cycle inhibitors: three families united by a common cause. Gene 247:1–15PubMedGoogle Scholar
  294. Vieira HL, Haouzi D, El Hamel C et al. (2000) Permeabilization of the mitochondrial inner membrane during apoptosis: impact of the adenine nucleotide translocator. Cell Death Differ 7:1146–1154PubMedGoogle Scholar
  295. Wagener C, Bargou RC, Daniel PT et al. (1996) Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int J Cancer 67:138–141PubMedGoogle Scholar
  296. Waldman T, Lengauer C, Kinzler KW, Vogelstein B (1996) Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381:713–716PubMedGoogle Scholar
  297. Wang JY (2000) Regulation of cell death by the Abl tyrosine kinase. Oncogene 19:5643–5650PubMedGoogle Scholar
  298. Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ (1996) BID: a novel BH3 domain-only death agonist. Genes Dev 10:2859–2869PubMedGoogle Scholar
  299. Wang ZG, Ruggero D, Ronchetti S et al. (1998) PML is essential for multiple apoptotic pathways. Nat Genet 20:266–272PubMedGoogle Scholar
  300. Wang H, Liu D, Wang Y, Qin J, Elledge S J (2001) Pds1 phosphorylation in response to DNA damage is essential for its DNA damage checkpoint function. Genes Dev 15:1361–1372PubMedGoogle Scholar
  301. Weber JD, Jeffers JR, Rehg JE et al. (2000) p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev 14:2358–2365PubMedGoogle Scholar
  302. Westendorp MO, Frank R, Ochsenbauer C et al. (1995) Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gpl20. Nature 375:497–500PubMedGoogle Scholar
  303. Whiteside D, McLeod R, Graham G et al. (2002) A homozygous germ-line mutation in the human msh2 gene predisposes to hematological malignancy and multiple caféau-lait spots. Cancer Res 62:359–362PubMedGoogle Scholar
  304. Whitman SP, Archer KJ, Feng L et al. (2001) Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 61:7233–7239PubMedGoogle Scholar
  305. Wieder T, Essmann F, Prokop A et al. (2001) Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor ligand interaction and occurs downstream of caspase-3. Blood 97:1378–1387PubMedGoogle Scholar
  306. Wiley SR, Schooley K, Smolak PJ et al. (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673–682PubMedGoogle Scholar
  307. Willis TG, Jadayel DM, Du MQ et al. (1999) Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96:35–45PubMedGoogle Scholar
  308. Wind N de, Dekker M, Claij N et al. (1999) HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions. Nat Genet 23:359–362PubMedGoogle Scholar
  309. Winston JT, Koepp DM, Zhu C, Elledge SJ, Harper JW (1999) A family of mammalian F-box proteins. Curr Biol 9:1180–1182PubMedGoogle Scholar
  310. Wu J, Gu L, Wang H, Geacintov NE, Li GM (1999) Mismatch repair processing of carcinogen-DNA adducts triggers apoptosis. Mol Cell Biol 19:8292–8301PubMedGoogle Scholar
  311. Wyllie AH (1980) Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284:555–556PubMedGoogle Scholar
  312. Wyllie AH, Bellamy CO, Bubb VJ et al. (1999) Apoptosis and carcinogenesis. Br J Cancer 80:34–37PubMedGoogle Scholar
  313. Yamada KM, Araki M (2001) Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 114:2375–2382PubMedGoogle Scholar
  314. Yamaguchi H, Inokuchi K, Sakuma Y, Dan K (2001) Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia. Leukemia 15:1729–1734PubMedGoogle Scholar
  315. Yamamoto YR, Gaynor B (2001) Therapeutic potential of inhibition of the NFκB pathway in the treatment of inflammation and cancer. J Clin Invest 107:135–142PubMedGoogle Scholar
  316. Yamasaki L (1999) Balancing proliferation and apoptosis in vivo: the Goldilocks theory of E2F/DP action. Biochim Biophys Acta 1423-.M9–15Google Scholar
  317. Yang E, Zha J, Jockei J, Boise LH, Thompson CB, Korsmeyer SJ (1995) Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80:285–291PubMedGoogle Scholar
  318. Yang J, Liu X, Bhalla K et al. (1997) Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275:1129–1132PubMedGoogle Scholar
  319. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchim Oren A (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345–347PubMedGoogle Scholar
  320. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B (2001) PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7:673–682PubMedGoogle Scholar
  321. Zha J, Harada H, Yang E, Jockei J, Korsmeyer SJ (1996) Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14–3–3 not Bcl-X(L). Cell 87:619–628PubMedGoogle Scholar
  322. Zhang H, Richards B, Wilson T et al. (1999) Apoptosis induced by overexpression of hMSH2 or hMLH1. Cancer Res 59:3021–3027PubMedGoogle Scholar
  323. Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z (2001) Arsenic trioxide, a therapeutic agent for APL. Oncogene 20:7146–7153PubMedGoogle Scholar
  324. Zhong S, Salomoni P, Ronchetti S, Guo A, Ruggero D, Pandolfi PP (2000) Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. J Exp Med 191:631–640PubMedGoogle Scholar
  325. Zhou BB, Elledge SJ (2000) The DNA damage response: putting checkpoints in perspective. Nature 408:433–439PubMedGoogle Scholar
  326. Zhou M, Gu L, Abshire TC et al. (2000) Incidence and prognostic significance of MDM 2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia 14:61–67PubMedGoogle Scholar
  327. Zhu J, Koken MH, Quignon F et al. (1997) Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:3978–983PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Peter Daniel

There are no affiliations available

Personalised recommendations